Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Stride, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm
December 22, 2020 18:00 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
ROSEN, A TOP RANKED LAW FIRM, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm – BIIB
December 22, 2020 13:50 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Biogen Inc. (NASDAQ: BIIB), between October 22, 2019 and...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cabot Oil & Gas, Biogen, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm
December 16, 2020 19:00 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cabot Oil & Gas, Biogen, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm
December 09, 2020 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, JOYY, Berry Corporation, and Pinterest and Encourages Investors to Contact the Firm
December 02, 2020 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Neovasc, Interface, and Biogen and Encourages Investors to Contact the Firm
November 24, 2020 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intercept Pharmaceuticals, Neovasc, Interface, and Biogen and Encourages Investors to Contact the Firm
November 18, 2020 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
November 13, 2020 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United...
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen, Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
November 12, 2020 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Biogen, Inc. (NASDAQ:...
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
October 30, 2020 07:00 ET
|
Biogen Inc.
If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and...